T. Williamson

The impact of antidepressant use on social functioning: reboxetine versus fluoxetine

H. Birnbaum, P. Greenberg, C. Rowland, 2000, International clinical psychopharmacology.

PUR3: PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER

C. Barr, T. Williamson, Zhiyuan Zhou, 2001 .

Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.

B. O'brien, R. Goeree, T. Williamson, 2001, Clinical therapeutics.

Intra-articular urokinase in rheumatoid arthritis.

W. Dick, R. Sturrock, T. Williamson, 1974, Annals of the Rheumatic Diseases.

Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.

J. A. Hall, J. W. Meyer, T. Williamson, 2000, Managed care interface.

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer.

M. Bates, A. Spiers, M. Zagari, 1997, Clinical therapeutics.

Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.

K. Tonkin, M. Bates, M. Zagari, 1996, The Canadian journal of oncology.